AMRN Amarin Corp

RNS Number:5047L
Amarin Corporation Plc
10 January 2008


    AMARIN TO COMMENCE PHASE II TRIAL WITH AMR101 IN AGE ASSOCIATED MEMORY
                                   IMPAIRMENT


LONDON, United Kingdom, January 10, 2008 - Amarin Corporation plc (NASDAQ: AMRN)
today announced that it has received the necessary regulatory and ethical
approvals to commence a Phase IIa trial in Age Associated Memory Impairment
(AAMI) with AMR101 (ultra-pure ethyl-EPA).


The Phase IIa trial will be a randomized, double-blind, placebo-controlled
study. The trial will enroll 96 patients with AAMI who will be randomized to
receive 1, 2 or 4 grams of AMR101 or placebo twice daily over a six-week period.
Efficacy will be assessed by a computerised battery of cognition tests designed
by Cognitive Drug Research (CDR) Ltd, a world leader in the provision of
innovative cognitive function assessment technology. The study is being
conducted in the U.K. and patient recruitment is expected to commence shortly,
with initial results expected in the second half of 2008.


Dr. Declan Doogan, Head of Research and Development at Amarin commented, "AMR101
has already demonstrated promising positive effects in classical preclinical
models of memory and cognition. We are pleased to receive approval to commence
this study with AMR101 and look forward to assessing its effects on AAMI, an
area of growing medical concern in all developed nations with aging
populations."


Amarin had previously announced positive results from a pre-clinical program in
memory and cognition using AMR101, conducted in collaboration with Professor
Marina Lynch, Department of Physiology, Institute of Neuroscience, Trinity
College, Dublin.

About Age Associated Memory Impairment (AAMI)


AAMI is a recognized syndrome relating to memory changes associated with normal
aging. AAMI is a common condition in individuals over 50 years of age. In the
United States, it is estimated that approximately 40% of people aged 65 and
above, or 16 million, have AAMI. It is characterized by gradual memory
impairment (subjective memory decline and objective memory loss) with the
absence of dementia. Individuals with AAMI have been shown to have a three-fold
greater risk for development of dementia than individuals who do not meet AAMI
criteria.


About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system and cardiovascular diseases. Our goal is to be a leader in the
research, development and commercialization of novel drugs that address unmet
patient needs.


Amarin's CNS development pipeline includes the recently acquired myasthenia
gravis clinical program and preclinical programs in neuromuscular, neuronal
degenerative and inflammatory diseases; Miraxion for Huntington's disease; two
programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is
initiating a series of cardiovascular preclinical and clinical programs to
capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin also has two proprietary technology platforms, a
lipid-based technology platform for the targeted transport of molecules through
the liver and/or to the brain, and a unique mRNA technology based on cholinergic
neuromodulation.


Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively.



Contacts:

Amarin

Thomas Lynch, Chairman and Chief Executive Officer, +44 (0) 1865 784 210

Alan Cooke, President and Chief Operating Officer, +353 (1) 669 9020

investor.relations@amarincorp.com


Investors:

Lippert/Heilshorn & Associates, Inc.

Anne Marie Fields +1 212 838 3777

Bruce Voss +1 310 691 7100


Media:

Powerscourt +44 (0) 207 250 1446

Rory Godson

Paul Durman

Sarah Daly


Disclosure Notice

The information contained in this document is as of January 10, 2008. Amarin
assumes no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: risks relating to the Company's ability to maintain its Nasdaq
listing (including the risk that the Company may not successfully appeal a
Nasdaq delisting determination); Amarin's ability to maintain sufficient cash
and other liquid resources to meet its operating and debt service requirements;
the success of Amarin's research and development activities, including its
planned clinical trials in cardiovascular disease and; decisions by regulatory
authorities regarding whether and when to approve Amarin's drug applications, as
well as their decisions regarding labeling and other matters that could affect
the commercial potential of Amarin's products; the speed with which regulatory
authorizations, pricing approvals and product launches may be achieved; the
success with which developed products may be commercialized; competitive
developments affecting Amarin's products under development; the effect of
possible domestic and foreign legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement, including under Medicaid
and Medicare in the United States, and involuntary approval of prescription
medicines for over-the-counter use; Amarin's ability to protect its patents and
other intellectual property; claims and concerns that may arise regarding the
safety or efficacy of Amarin's product candidates; governmental laws and
regulations affecting Amarin's operations, including those affecting taxation;
general changes in International and US generally accepted accounting
principles; and growth in costs and expenses. A further list and description of
these risks, uncertainties and other matters can be found in Amarin's Form 20-F
for the fiscal year ended December 31, 2006, filed with the SEC on March 5,
2007, Amarin's statutory annual report for the year ended 31 December, 2006
furnished on a Form 6-K to the SEC on May 9, 2007, Amarin's Report of Foreign
Issuer (Updated and Additional Risk Factors) furnished on a Form 6-K to the SEC
on January 8, 2008 and in Amarin's other Reports of Foreign Issuer on Form 6-K
furnished to the SEC.


                                     # # #







                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRURSARWRRAAAR

Amarin (LSE:AMRN)
Historical Stock Chart
From Apr 2024 to May 2024

Amarin (LSE:AMRN)
Historical Stock Chart
From May 2023 to May 2024